ArticleIn vivo (Athens, Greece)

Claudin 18.2 Is Not a Promising Biomarker for Targeted Immunotherapy in Prostatic Cancers.

Jina Baek et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.